Oncostellae

Executive Summary

Oncostellae is a Barcelona-based biotechnology company focused on discovering and developing novel small-molecule drugs with innovative chemical scaffolds. The company targets clinically validated therapeutic pathways in oncology and inflammatory/autoimmune diseases, aiming to provide differentiated treatment options. Its lead candidate is in Phase 1/2 clinical development, with plans to demonstrate proof-of-concept in targeted indications. Oncostellae's proprietary scaffold technology and focus on validated targets position it to address high unmet medical needs, though the company remains in early clinical stages with limited public pipeline details. Key risks include competition from other small-molecule developers and the need for additional financing to advance its programs. With a solid scientific foundation and a clear focus on novel chemotypes, Oncostellae represents an early-stage investment opportunity in the precision oncology and autoimmune space.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 interim data readout for lead oncology program40% success
• Q3 2026Series B financing round to fund ongoing clinical trials60% success
• Q1 2027FDA orphan drug designation for lead candidate in rare cancer indication30% success